Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in <i>RAS</i> and <i>BRAF</i> WT mCRCCarmine Pinto, Armando Orlandi, Francesca Fenizia et al.|Future Oncology|2018Cited by 7
Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.Carmine Pinto, Nicola Normanno, Armando Orlandi et al.|Journal of Clinical Oncology|2017Cited by 3